Q-omics provides the consensus-scored TOMM22P6 profile across patient tissues and cancer cell-line models. TOMM22P6 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in MESO. Additionally, TOMM22P6 RNA expression shows 5,210 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, and STAD as cancer lineages where TOMM22P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.